MIGUEL ÁNGEL
CALLEJA HERNÁNDEZ
Investigador en el període 2016-2017
Hospital Universitario Virgen de las Nieves
Granada, EspañaPublicacions en col·laboració amb investigadors/es de Hospital Universitario Virgen de las Nieves (48)
2024
-
Factors Contributing to Negative Outcomes Associated with Medications and Drug-Related Problems in Kidney Replacement Therapy—A Hospital-Based Prospective Observational Study
Journal of Clinical Medicine, Vol. 13, Núm. 4
2023
-
Clinical Outcomes of First-line Therapies for Advanced Non-Small Cell Lung Cancer: A Systematic Review of Trials Published Between 2010 and 2020
American journal of clinical oncology, Vol. 46, Núm. 10, pp. 433-438
-
Medication Review with Follow-Up for End-Stage Renal Disease: Drug-Related Problems and Negative Outcomes Associated with Medication—A Systematic Review
Journal of Clinical Medicine, Vol. 12, Núm. 15
2021
-
Analyzing the clinical benefit of newer therapies for advanced or metastatic non-small-cell lung cancer: application of the ESMO-magnitude of clinical benefit scale v1.1
Acta Oncologica, Vol. 60, Núm. 9, pp. 1225-1232
-
Association between polymorphisms in the vitamin D receptor and susceptibility to multiple sclerosis
Pharmacogenetics and Genomics, Vol. 31, Núm. 2, pp. 40-47
-
Genetic polymorphisms on the effectiveness or safety of breast cancer treatment: Clinical relevance and future perspectives
Mutation Research - Reviews in Mutation Research, Vol. 788
-
Impact of a risk-sharing agreement in rheumatoid arthritis in Spain
Health Policy, Vol. 125, Núm. 3, pp. 335-340
-
Pharmacogenetic Predictors of Response to Interferon Beta Therapy in Multiple Sclerosis
Molecular Neurobiology, Vol. 58, Núm. 9, pp. 4716-4726
-
Therapeutic value of single nucleotide polymorphisms on the efficacy of new therapies in patients with multiple sclerosis
Journal of Personalized Medicine, Vol. 11, Núm. 5
2020
-
Association of ABCB1 and VEGFA gene polymorphisms with breast cancer susceptibility and prognosis
Pathology Research and Practice, Vol. 216, Núm. 4
-
Effect of genetic polymorphisms on therapeutic response in multiple sclerosis relapsing-remitting patients treated with interferon-beta
Mutation Research - Reviews in Mutation Research, Vol. 785
-
Pharmacist recommendations for carbapenem de-escalation in urinary tract infection within an antimicrobial stewardship program
Journal of Infection and Public Health, Vol. 13, Núm. 4, pp. 558-563
2019
-
Clinical outcomes of carbapenem de-escalation regardless of microbiological results: A propensity score analysis
International Journal of Infectious Diseases, Vol. 85, pp. 80-87
2017
-
Cytokine single-nucleotide polymorphisms and risk of non-small-cell lung cancer
Pharmacogenetics and Genomics, Vol. 27, Núm. 12, pp. 438-444
-
Impact of pharmaceutical care on cardiovascular risk among older HIV patients on antiretroviral therapy
International Journal of Clinical Pharmacy, Vol. 39, Núm. 1, pp. 52-60
-
Pharmacotherapy follow-up of patients under treatment with biologic agents for chronic inflammatory systemic conditions: An agreement among hospital pharmacists for the standardized collection of a minimum set of data
Farmacia Hospitalaria, Vol. 41, Núm. 1, pp. 31-48
-
Safe implementation of standard concentration infusions in paediatric intensive care
Journal of Pharmacy and Pharmacology, Vol. 69, Núm. 5, pp. 529-536
2016
-
Cardiovascular risk in hiv patients aged 50 years and over on antiretroviral therapy: An observational follow-up study
Latin American Journal of Pharmacy, Vol. 35, pp. 1083-1091
-
Effectiveness and safety of pemetrexed for non-small cell lung cancer in the Andalusian Public Health System
Farmacia Hospitalaria, Vol. 40, Núm. 6, pp. 477-485
-
Seguimiento a largo plazo de pacientes con disfunción ventricular izquierda intervenidos de sustitución valvular aórtica. Experiencia en nuestra institución
Cirugia Cardiovascular, Vol. 23, Núm. 4, pp. 174-178